The role of human transferrin in tracking neurodegenerative disorders
Maintaining healthy iron levels is essential for functions across the brain and body. At the center of this balancing act is human transferrin — the glycoprotein that binds to and transports iron throughout the body, including the central nervous system (CNS). While its day job is to maintain iron homeostasis, transferrin is also gaining attention as a biomarker in neurodegenerative disorders. But how do the levels of this protein relate to the disease states of Alzheimer’s, Parkinson’s, and multiple sclerosis (MS)?
Iron transport and CNS homeostasis
Transferrin is the primary iron transport protein in humans. It binds iron in the blood and delivers it to cells via the transferrin receptor TfR1. This is especially important in the brain, where neurons and glia require iron for mitochondrial function, neurotransmitter synthesis, and myelination1. In the CNS, transferrin also helps buffer iron levels, limiting oxidative stress caused by free iron2, and acts as the essential protein for iron uptake across the blood-brain barrier (BBB)3.
Transferrin in Alzheimer’s, Parkinson’s, and MS
Changes to iron and transferrin concentrations in blood plasma, cerebral spinal fluid (CSF), and brain matter have been linked to multiple neurodegenerative diseases:
-
Iron accumulation may contribute to oxidative stress and the dopaminergic neuron degeneration in the substantia nigra (SN) that characterizes PD6.
-
Altered transferrin levels have been reported in PD patients, including a correlation between plasma transferrin levels and the tremor-dominant phenotype of PD7.
These findings position transferrin as a potential fluid biomarker for tracking neurodegenerative disease-related changes in iron metabolism and even as a potential therapeutic target.
Why is human transferrin attractive for biomarker development?
Transferrin has several properties that make it a compelling candidate for biomarker panels. Its three key advantages are:
-
Stability: Transferrin is relatively stable in biofluids, making it suitable for routine sample collection and storage.
-
Broad availability: One of transferrin’s strengths as a biomarker is its presence in multiple accessible fluids, particularly plasma and CSF. (While CSF is often preferred for CNS-specific biomarkers, plasma offers a less invasive alternative.)
-
Assay compatibility: Transferrin detection is compatible with widely used analytical platforms such as ELISA, western blotting, and liquid chromatography-mass spectrometry (LC-MS), simplifying assay development and standardization.
These features make human transferrin easy to integrate into multiplex biomarker panels for neurodegeneration.
Barriers to biomarker status
Despite its potential, measuring transferrin isn’t without challenges. Firstly, there are two main isoforms of human transferrin: serum-type and brain-type10. These isoforms differ in their glycosylation patterns, but not by much, making assay development more demanding and often requiring high-resolution techniques to distinguish them accurately11. Secondly, research into transferrin as a biomarker is rife with variability. Differences in measurement of total transferrin, specific isoforms, or iron saturation can make cross-study comparisons difficult, and inter-individual variability (in baseline levels, glycosylation status, or disease state) can further complicate interpretation.
Since transferrin is also a general maker of nutrition and inflammation, context is critical. Elevation to disease-specific biomarker status is still a way off and must be supported by carefully controlled clinical studies.
A role in early detection and patient stratification
Human transferrin is unlikely to replace classic neurodegeneration markers like tau or neurofilament light chain (NfL), but its unique link to iron metabolism and CNS function gives it complementary power. As part of panels paired with markers of neurodegeneration or inflammation, it may help:
-
Detect early, pre-symptomatic changes in iron homeostasis
-
Differentiate inflammatory vs. degenerative disease states
-
Stratify patients based on progression risk or therapeutic response
-
Provide a more complete view of disease mechanisms
For researchers building fluid biomarker panels — or for clinicians seeking less invasive tools — transferrin offers an iron-informed view of neurodegeneration, grounded in biology and increasingly supported by data.
References
(1) Hare, D. J.; Ayton, S.; Bush, A. I.; Lei, P. A Delicate Balance: Iron Metabolism and Diseases of the Brain. Front. Aging Neurosci. 2013, 5. https://doi.org/10.3389/fnagi.2013.00034.
(2) Ward, R. J.; Dexter, D. T.; Crichton, R. R. Iron, Neuroinflammation and Neurodegeneration. Int. J. Mol. Sci. 2022, 23 (13), 7267. https://doi.org/10.3390/ijms23137267.
(3) McCarthy, R. C.; Kosman, D. J. Mechanisms and Regulation of Iron Trafficking across the Capillary Endothelial Cells of the Blood-Brain Barrier. Front. Mol. Neurosci. 2015, 8. https://doi.org/10.3389/fnmol.2015.00031.
(4) LeVine, S. M. Exploring Potential Mechanisms Accounting for Iron Accumulation in the Central Nervous System of Patients with Alzheimer’s Disease. Cells 2024, 13 (8), 689. https://doi.org/10.3390/cells13080689.
(5) Tian, S.; Wang, B.; Ding, Y.; Zhang, Y.; Yu, P.; Chang, Y.-Z.; Gao, G. The Role of Iron Transporters and Regulators in Alzheimer’s Disease and Parkinson’s Disease: Pathophysiological Insights and Therapeutic Prospects. Biomed. Pharmacother. 2024, 179, 117419. https://doi.org/10.1016/j.biopha.2024.117419.
(6) Medeiros, M. S.; Schumacher-Schuh, A.; Cardoso, A. M.; Bochi, G. V.; Baldissarelli, J.; Kegler, A.; Santana, D.; Chaves, C. M. M. B. S.; Schetinger, M. R. C.; Moresco, R. N.; Rieder, C. R. M.; Fighera, M. R. Iron and Oxidative Stress in Parkinson’s Disease: An Observational Study of Injury Biomarkers. PLOS ONE 2016, 11 (1), e0146129. https://doi.org/10.1371/journal.pone.0146129.
(7) Si, Q.-Q.; Yuan, Y.-S.; Zhi, Y.; Tong, Q.; Zhang, L.; Zhang, K. Plasma Transferrin Level Correlates with the Tremor-Dominant Phenotype of Parkinson’s Disease. Neurosci. Lett. 2018, 684, 42–46. https://doi.org/10.1016/j.neulet.2018.07.004.
(8) Zierfuss, B.; Wang, Z.; Jackson, A. N.; Moezzi, D.; Yong, V. Iron in Multiple Sclerosis – Neuropathology, Immunology, and Real-World Considerations. Mult. Scler. Relat. Disord. 2023, 78. https://doi.org/10.1016/j.msard.2023.104934.
(9) (PDF) Iron, Transferrin and Ferritin Concentrations in the Cerebrospinal Fluid of Multiple Sclerosis Patients in Comparison to Controls. ResearchGate.
(10) Murakami, Y.; Saito, K.; Ito, H.; Hashimoto, Y. Transferrin Isoforms in Cerebrospinal Fluid and Their Relation to Neurological Diseases. Proc. Jpn. Acad. Ser. B 2019, 95 (5), 198–210. https://doi.org/10.2183/pjab.95.015.
(11) Baerenfaenger, M.; Post, M. A.; Langerhorst, P.; Huijben, K.; Zijlstra, F.; Jacobs, J. F. M.; Verbeek, M. M.; Wessels, H. J. C. T.; Lefeber, D. J. Glycoproteomics in Cerebrospinal Fluid Reveals Brain-Specific Glycosylation Changes. Int. J. Mol. Sci. 2023, 24 (3), 1937. https://doi.org/10.3390/ijms24031937.